10-Q: DarioHealth Corp. Reports Second Quarter 2024 Results, Impacted by Twill Acquisition and Workforce Reduction

DarioHealth Corp.'s Q2 2024 results show a mixed picture with revenue growth offset by increased expenses and a significant workforce reduction, alongside the integration of Twill.

Summary

• DarioHealth Corp. reported a net loss of $13.61 million for the three months ended June 30, 2024, and $20.785 million for the six months ended June 30, 2024.
• Revenue for the quarter was $6.255 million, a slight increase of 1.7% compared to the same period last year, while six-month revenue decreased by 9.1% to $12.013 million.
• The company's gross profit for the quarter was $2.756 million, representing 44.1% of revenues, and $5.188 million for the six months, representing 43.2% of revenues.
• Operating expenses totaled $18.947 million for the quarter and $39.234 million for the six months, driven by increased research and development, sales and marketing, and general and administrative costs.
• The company completed the acquisition of Twill, Inc. in February 2024, which contributed to revenue and expenses.
• A workforce reduction of 88 employees, approximately 30% of the total workforce, was implemented during the quarter to reduce operating expenses.
• The company's cash and cash equivalents stood at $22.938 million as of June 30, 2024, compared to $36.797 million at the end of 2023.
• The company has an accumulated deficit of $363.474 million and used $24.473 million in operating activities during the first six months of 2024.
• DarioHealth is dependent on raising additional funds to fund its operations and there is substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive developments like improved gross profit and new contracts, but the significant net losses, cash burn, workforce reduction, and going concern warning create a negative overall sentiment. The company faces significant financial challenges and needs to demonstrate a clear path to profitability.

Positives

• Gross profit margin improved to 44.1% in Q2 2024, indicating better profitability on sales.
• Net loss decreased by 17.9% in Q2 2024 compared to Q2 2023, showing some improvement in financial performance.
• The acquisition of Twill is expected to provide synergies and expand the company's product offering and commercial channels.
• The company secured a new contract with a national employer to provide its cardiometabolic solution with integrated support for GLP-1s.
• Clinical studies presented at the ADA conference showed positive results for Dario's ability to help members improve blood glucose levels and achieve diabetes remission.

Negatives

• The company experienced a decrease in revenue of 9.1% for the six months ended June 30, 2024, compared to the same period in 2023.
• Operating expenses increased significantly, driven by higher payroll and other costs, impacting profitability.
• The company incurred a net loss of $13.61 million for the quarter and $20.785 million for the six months ended June 30, 2024.
• The company's cash reserves decreased significantly to $22.938 million as of June 30, 2024.
• The company has an accumulated deficit of $363.474 million, raising concerns about its long-term financial stability.
• The company's financial position raises substantial doubt about its ability to continue as a going concern.
• A price concession of $1.088 million was provided to a preferred partner, reducing revenue for the period.

Risks

• The company's financial position raises substantial doubt about its ability to continue as a going concern.
• The company is dependent on raising additional funds to fund its operations.
• The company's revenues are concentrated with a major customer, and the loss of this customer could significantly impact revenue.
• Political, economic, and military instability in Israel, where the company has significant operations, could adversely affect the business.
• The market price of the company's common stock has been extremely volatile and may continue to be volatile.
• The company may be unable to scale up its commercial launch of its products or meet its commercial sales targets.
• The company may be unable to obtain additional capital resources in the near term.

Future Outlook

The company intends to fund its future operations through cash on hand, additional private and/or public offerings of debt or equity securities or a combination of the foregoing. The company expects to continue to generate losses for the foreseeable future and its transition to profitability is dependent upon, among other things, the successful development and commercialization of the company's products and the achievement of a level of revenues adequate to support the cost structure.

Management Comments

• Management believes that the proceeds from the prior private placements and the Avenue Loan Facility and the funds we may draw down from the Sales Agreement, combined with our cash on hand and short-term investments are sufficient to meet our obligations as they come due for at least a period of twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.
• Management believes that our innovative approach to digital therapeutics disrupts the traditional provider-centered system of healthcare delivery by offering user-centric care that is continuous, customized supportive of better overall health.

Industry Context

The company operates in the digital therapeutics market, which is experiencing growth as healthcare providers and payers seek cost-effective solutions for managing chronic conditions. The acquisition of Twill positions DarioHealth to compete more effectively in this market by offering a broader range of solutions. The company's focus on a B2B2C model aligns with industry trends of partnering with employers and health plans to reach a wider audience.

Comparison to Industry Standards

• DarioHealth's gross profit margin of 44.1% in Q2 2024 is comparable to other digital health companies, but the company's high operating expenses and net losses are a concern.
• The company's reliance on a single major customer is a risk, as many digital health companies aim to diversify their revenue streams.
• The workforce reduction of 30% is a significant move, indicating the company is taking steps to control costs, which is a common strategy in the industry when facing financial challenges.
• The company's focus on multi-condition management is in line with the industry trend of providing integrated solutions for co-occurring chronic conditions.
• The company's clinical studies and publications are important for establishing credibility and demonstrating the effectiveness of its solutions, which is a key factor for success in the digital health market.
• Compared to companies like Livongo (now part of Teladoc), DarioHealth is still in an earlier stage of growth and needs to demonstrate consistent revenue growth and profitability.

Management Changes

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential need for further dilution.
• Employees have been impacted by the workforce reduction.
• Customers may be affected by changes in the company's operations and product offerings.
• Creditors face increased risk due to the company's financial challenges.

Next Steps

• The company will continue to integrate Twill into its operations.
• The company will focus on reducing operating expenses.
• The company will seek additional funding through various means.
• The company will continue to develop and commercialize its products.
• The company will continue to monitor and manage its financial position.

Key Dates

Keywords

Digital Therapeutics, Chronic Conditions, Diabetes, Hypertension, Weight Management, Musculoskeletal Health, Behavioral Health, Twill Acquisition, Workforce Reduction, Financial Results, B2B2C, GLP-1, Healthcare, Digital Health